ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Trubion Pharmaceuticals has partnered with Facet Biotech to commercialize TRU-016, a Trubion product in Phase I clinical trials for the treatment of chronic lymphocytic leukemia. Facet will pay a $20 million up-front fee and buy $10 million in Trubion stock. Trubion could gain another $177 million in milestones as the drug progresses toward the market. TRU-016 is a small modular immunopharmaceutical (SMIP) protein, basically a monoclonal antibody that is one-third to one-half the size of a traditional antibody drug. Trubion uses combinatorial chemistry to assemble SMIPs with a binding domain, a hinge domain, and an effector domain.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X